DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
This is a post-authorisation safety study to assess the incidence and severity of all
 pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect &
 describe less common adverse drug reactions, and to summarise DYNEPO drug utilisation.
Inclusion Criteria:

 -  Adult patients must have established Chronic Kidney Disease (CKD) and be willing and
 able to provide written informed consent.

 -  Patients must already be receiving DYNEPO treatment at time of study entry.

 -  Patients who are likely to receive DYNEPO for at least 1 year.

 Exclusion Criteria:

 -  Known intolerance to EPO of any of its excipients

 -  Known of suspected Pure Red Cell Aplasia (PRCA)